NCT03415594View on ClinicalTrials.gov

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

November 21, 2019

Study Completion Date

November 21, 2019

Conditions
Short Bowel Syndrome
Interventions
DRUG

FE203799 GLP-2 analogue

FE203799 5 mg subQ once weekly

DRUG

FE203799 Placebo GLP-2 analogue

Placebo subQ once weekly

DRUG

FE203799 GLP-2 analogue

FE203799 10 mg subQ once weekly

Trial Locations (1)

Unknown

Rigshospitalet, Copenhagen

Sponsors
All Listed Sponsors
collaborator

VectivBio AG

INDUSTRY

lead

GlyPharma Therapeutics

INDUSTRY